Abstracts
MDM personnel regularly present their research at scientific conferences such as the Society for
Medical Decision Making (SMDM) and the International Society for Pharmacoeconomics and Outcomes
Research (ISPOR). Additionally, MDM personnel are regular reviewers for conference presentations at
SMDM and ISPOR.
Smolen LJ, Klein RW Synchronization of random number streams greatly enhances efficiency of
probabilistic models (Poster PMC15 ISPOR 15th Annual International Meeting, Atlanta, GA, May 17, 2010)
Klein R, Lawson AH, Muehlenbein CE, Liepa AM, Wielage RC, Babineaux S, Koustenis AG The
budgetary impact of pemetrexed maintenance therapy for advanced nonsquamous non-small cell lung cancer (Poster
PCN25 ISPOR 15th Annual International Meeting, Atlanta, GA, May 17, 2010)
Ohsfeldt R, Gandhi SK, Jensen MM, Smolen L, Fox KM, Hsia J, Gold A Cost-effectiveness of rosuvastatin
20 mg in secondary-prevention patients in the United States (Poster PCV70 ISPOR 15th Annual International Meeting
, Atlanta, GA, May 19, 2010)
Smolen H, Klein R, Myers Accounting for trial-excluded medical conditions when simulating mortality
in clinical trial populations (Poster PCV157 ISPOR 15th Annual International Meeting, Atlanta, GA, May 19, 2010)
Furiak NM, Bansal M. The estimated cost-savings of stratified care for migraine headaches
from a U.S. perspective (Poster PND6 ISPOR 15th Annual Meeting, Atlanta, GA May 17, 2010)
Klein RW, Lawson AH, Muehlenbein CE, Liepa AM, Wielage RC, Babineaux S, Koustenis A.
Budgetary impact of pemetrexed as maintenance therapy for advanced non-small cell lung cancer. (Poster PRR-22
Academy of Managed Care Pharmacy 22nd Annual Meeting: San Diego, CA; April 9, 2010)
Smolen HJ, Klein TM, Klein RW, Cohen DJ. Determining a model-derived relative stroke
riskthreshold to justify carotid stenting in surgical high-risk patients. (Poster PCV45 ISPOR
12th Annual European Congress, Paris France, Oct 24, 2009)
Klein R, Muehlenbein C, Wielage R, Liepa A, Babineaux S, Schwartzberg L. The importance of
histology in evaluating the cost-effectiveness of pemetrexed maintenance after first-line therapy
for advanced non-small cell lung cancer. (Poster 19HSR 31st Annual Meeting of the Society for Medical
Decision Making, Hollywood, CA, Oct 20, 2009)
Kahle-Wrobleski K, Klein R, Furiak N, Siemers E, Klein T.
Biomarker screening for Alzheimer's Disease: When to screen and how
often? (ICAD July 2009)
Ascher-Svanum H, Furiak NM, Klein RW, Montgomery W, Smolen
LJ, Lawson AH, Conley RR. Cost-effectiveness of Olanzipine
Long-acting Injection in the Treatment of Non-adherence patients with
Schizophrenia in the United States (Poster PMH21 ISPOR 14th Annual
International Meeting, Orlando FL, May, 2009)
Muehlenbein C, Wielage R, Liepa A, Babineaux S, Klein R,
Schwartzberg L. The Budgetary Impact of Pemetrexed plus Cisplatin as
First-line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer.
(Poster PCN20 ISPOR 14th Annual International Meeting, Orlando FL, May,
2009)
Klein TM, Wielage RC, Furiak NM, Klein RW. Using an
Encounter-Based Database to Validate a Disease Progression Model:
Lessons for Modelers. (Poster PMC30 ISPOR 14th Annual International
Meeting, Orlando FL, May, 2009)
Kahle-Wrobleski K, Siemers ER, Sarpong E, Furiak N, Klein T,
Klein R, Callahan C. Biomarker screening for Alzheimer's Disease:
Sensitivity and specificity parameters (Poster 61st American Academy of
Neurology Annual Meeting Seattle, WA April 2009)
Smolen HJ, Einterz RM. A Simulation-based Approach to
Modeling the Effects of Intervention Strategies on the Spread of
Meningococcal Meningitis. (Poster PIN3 ISPOR 11th Annual European
Congress, Athens Greece, Nov 2008).
Furiak NM, Kahle-Wrobleski K, Siemers ER, Klein TM,
Sarpong E, Klein RW. Modeling Screening and Prevention of
Alzheimer's Disease. (Poster 30th Annual Meeting of the Society for
Medical Decision Making, Philadelphia PA, Oct 20, 2008)
Ascher-Svanum H, Furiak NM, Klein RW, Smolen LJ, Watson, P.
Cost-effectiveness of Orally Disssolving Olanzipine Tablets in the
Treatment of Schizophrenia in the USA. Value in Health 2008;
11(3): A121. (Poster PMH35 ISPOR 13th Annual International Meeting,
Toronto CA, May, 2008).
Kessler WR, Klein RW, Wielage RC, Rex DK. Cost Savings of
Removing Diminutive Polyps Without Histological Assessment. Gastrointestinal
Endoscopy 2008; 67(5): AB105.
Ascher-Svanum H, Furiak NM, Klein RW, Smolen LJ, Zhu B.
Cost-effectiveness of Olanzapine versus Generic Risperidone and other
Antipsychotics in Standard Oral Formulations in Patients with
Schizphrenia in the US. Value in Health 2007; 10(6): A294.
(Poster PMH23 ISPOR 10th Annual European Congress, Dublin Ireland, Oct
21, 2007).
Klein RW, Yaesoubi R, Roberts SD. Factor Screening for
Parsimony of Variables in Pharmacoeconomic Models. Value in Health
2007; 10(3): A55. (Poster PCV62 ISPOR 12th Annual International
Meeting, Arlington VA, May 21, 2007).
Yaesoubi R, Roberts SD, Klein RW, Chalasani NP, Imperiale
TF. Factor Screening to Identify Factors Which Influence Strategy
Selection. (Poster III-2 28th Annual Meeting of the Society for Medical
Decision Making, Cambridge MA, October 17, 2006).
Klein RW, Imperiale TF, Chalasani N. A Cost effectiveness
Analysisof Screening for Esophageal Varices: How Good Does A Clinical
Decision Aid Have to Be? Value in Health 2006; 9(3): A45.
(Poster PG18 ISPOR 11th Annual International Meeting, Philadelphia PA,
May 22, 2006.)
Thomas NA, Zhu B, Ascher-Svanum H, Faries D, Montgomery W, Furiak
NM. Adherence Levels and Differential Use of Mental Health Services
in the Treatment of Schizophrenia. Value in Health 2006; 9(3):
A76. (Poster PMH38 ISPOR 11th Annual International Meeting,
Philadelphia PA, May, 2006)
Imperiale TF, Klein RW, Chalasani N. A cost-effectiveness
and cost-utility analysis of variceal ligation versus beta-blockers for
primary prophylaxis of variceal bleeding. Gastroenterology
2006; 130 (4): A810.
Russell JM, Furiak N, Klein R, Yurgin N, Marciniak M,
Bowman L. Using a generalized anxiety disorder disease state model to
quantify the effects of effective diagnosis and treatment on overall
remission rates. European Neuropsychopharmacology The Journal of
the European College of Neuropsychopharmacology 2005, 15(S3): S553.
Klein RW, Ohsfeldt RL, Smolen LJ, McCollam PL.
Potential 30-day Cost Savings From Acute Coronary Syndrome Treatment
Improvements. American College Clinical Pharmacists, San Francisco, May
2005.
Rousculp MD, Klein RW, Smolen LJ, Ohsfeldt RL, Johnston JA.
Cost-Effectiveness of Pharmacological Treatment in Postmenopausal
Women. Medical Decision Making 2005. (Poster I-11 SMDM 28th
Annual Meeting, San Francisco CA, October, 2005.)
Klein RW, Ohsfeldt RL, Smolen LJ, McCollam PL.
Potential Cost Savings From Acute Coronary Syndrome Treatment
Improvements. Value in Health 2005; 8(3): 262. (Poster PCV5
ISPOR 10th Annual International Meeting, Washington DC, May, 2005.)
Smolen HJ, Ohsfeldt RL, Klein RW, Poret AW,
Weinberger MH. An ARB Cost-Effectiveness Model Treating
Mild-to-Moderate Hypertension. Value in Health 2004; 7(3): 326.
(Poster PCV28 ISPOR 9th Annual International Meeting, Arlington VA,
May, 2004.) >
Ohsfeldt RL, Kreder KJ, Klein R, Chrischilles EC.
Cost-Effectiveness of Tamsulosin, Doxazosin, and Terazosin in the
Treatment of Benign Prostatic Hyperplasia. Value in Health
2003; 6(3): 288. (Poster PRK9 ISPOR 8th Annual International Meeting,
Arlington VA, May, 2003.)
Imperiale TF, Chalasani N, Klein RW. Cost-Effectness
Analysis of Measuring Hemodynamic Response to Primary
Pharmacoprophylaxis for Variceal Bleeding. Medical Decision Making
2001; 21(6): 528.
Ness RM, Klein RW, Holmes AM, Dittus RS. Is an increased
frequency of rescreening cost-effective in patients with a family
history of colorectal cancer? Gastroenterology 2000; 118: A264.
Ness RM, Klein RW, Holmes AM, Dittus RS. What is the
Cost-utility of Post-Polypectomy Colonoscopy Surveillance Strategies in
Persons With a Family History of Colorectal Cancer? Medical
Decision Making 1999, 19(4): 527.
Ness RM, Klein RW, Holmes AM, Dittus RS. What is the
Cost-utility of Colonscopic Re-screening in Persons with a Family
History of Colorectal Cancer but No Adenoma on Initial Screening? Medical
Decision Making 1999, 19(4): 544.
Ness RM, Klein RW, Holmes AM, Dittus RS. Is Rescreening
Cost-effective When no Polyps are Found at Initial Screening? Gastroenterology
1999; 116: A84.
Ness RM, Klein RW, Holmes AM, Dittus RS. What is the Effect
of Initial Screening Age on the Cost-Effectiveness of Post-Polypectomy
Surveillance. Gastroenterology 1999; 116: A84.
